skip to main content
Idioma:
Refinado por: assunto: Biological And Medical Sciences remover assunto: Tumors remover Male remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

AMADORI, Sergio ; SUCIU, Stefan ; THOMAS, Xavier ; LATAGLIATA, Roberto ; HALKES, Constantijn J. M ; FALZETTI, Franca ; MAGRO, Domenico ; GUIMARAES, José E ; BERNEMAN, Zwi ; SPECCHIA, Giorgina ; KARRASCH, Matthias ; FAZI, Paola ; STASI, Roberto ; VIGNETTI, Marco ; WILLEMZE, Roel ; DE WITTE, Theo ; MARIE, Jean-Pierre ; SALIH, Helmut R ; SELLESLAG, Dominik ; MUUS, Petra ; DE FABRITIIS, Paolo ; VENDITTI, Adriano ; HO, Anthony D ; LÜBBERT, Michael

Journal of clinical oncology, 2013-12, Vol.31 (35), p.4424-4430 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Amato, Robert J. ; Jac, Jaroslaw ; Giessinger, Sarah ; Saxena, Somyata ; Willis, James P.

Cancer, 2009-06, Vol.115 (11), p.2438-2446 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
3
Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report
Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report

Angiolillo, Anne L. ; Whitlock, J. ; Chen, Z. ; Krailo, M. ; Reaman, G.

Pediatric Blood & Cancer, 2006-02, Vol.46 (2), p.193-197 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
4
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

ARMAND, Philippe ; NAGLER, Arnon ; FAY, Joseph W ; RIZZIERI, David A ; HOSING, Chitra M ; BALL, Edward D ; UBERTI, Joseph P ; LAZARUS, Hillard M ; MAPARA, Markus Y ; GREGORY, Stephanie A ; TIMMERMAN, John M ; ANDORSKY, David ; WELLER, Edie A ; OR, Reuven ; WALLER, Edmund K ; ROTEM-YEHUDAR, Rinat ; GORDON, Leo I ; DEVINE, Steven M ; AVIGAN, David E ; CHEN, Yi-Bin ; KAMINSKI, Mark S ; KENT HOLLAND, H ; WINTER, Jane N ; MASON, James R

Journal of clinical oncology, 2013-11, Vol.31 (33), p.4199-4206 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

BENGALA, C ; GUARNERI, V ; RICCI, S ; MOSCA, F ; DEL TACCA, M ; CONTE, P. F ; GIOVANNETTI, E ; LENCIONI, M ; FONTANA, E ; MEY, V ; FONTANA, A ; BOGGI, U ; DEL CHIARO, M ; DANESI, R

British journal of cancer, 2005-07, Vol.93 (1), p.35-40 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
6
Analysis of in-field control and late toxicity for adults with early-stage hodgkin’s disease treated with chemotherapy followed by radiotherapy
Analysis of in-field control and late toxicity for adults with early-stage hodgkin’s disease treated with chemotherapy followed by radiotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Analysis of in-field control and late toxicity for adults with early-stage hodgkin’s disease treated with chemotherapy followed by radiotherapy

Chronowski, Gregory M ; Wilder, Richard B ; Tucker, Susan L ; Ha, Chul S ; Younes, Anas ; Fayad, Luis ; Rodriguez, Maria A ; Hagemeister, Fredrick B ; Barista, Ibrahim ; Cabanillas, Fernando ; Cox, James D

International journal of radiation oncology, biology, physics, 2003, Vol.55 (1), p.36-43 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
7
A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas
A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas

Churpek, Jane E. ; Pro, Barbara ; van Besien, Koen ; Kline, Justin ; Conner, Kathy ; Wade, James L. ; Hagemeister, Fredrick ; Karrison, Theodore ; Smith, Sonali M.

Cancer, 2013-05, Vol.119 (9), p.1683-1689 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
8
AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia
AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia

Cooper, Todd M. ; Alonzo, Todd A. ; Gerbing, Robert B. ; Perentesis, John P. ; Whitlock, James A. ; Taub, Jeffrey W. ; Horton, Terzah M. ; Gamis, Alan S. ; Meshinchi, Soheil ; Loken, Michael R. ; Razzouk, Bassem I.

Cancer, 2014-08, Vol.120 (16), p.2482-2489 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível

Citações Citado por
9
Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients
Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients

Derhovanessian, Evelyna ; Adams, Victoria ; Hähnel, Karin ; Groeger, Andrea ; Pandha, Hardev ; Ward, Stephen ; Pawelec, Graham

International journal of cancer, 2009-09, Vol.125 (6), p.1372-1379 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
10
Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response
Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response
Material Type:
Artigo 		Adicionar ao Meu Espaço

Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response

Dietz, Andrew C. ; DeFor, Todd E. ; Brunstein, Claudio G. ; Wagner, John E.

British journal of haematology, 2014-07, Vol.166 (2), p.209-212 [Periódico revisado por pares]

Oxford: Blackwell

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2003  (2)
  2. 2003Até2004  (3)
  3. 2005Até2006  (4)
  4. 2007Até2009  (15)
  5. Após 2009  (32)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.